In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Bank of America Securities analyst Allen Lutz maintained a Hold rating on Cencora (COR – Research Report) today. The company’s shares opened ...

Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

In an interview with Futurism, veteran psychiatrist and ADHD specialist William Dodson revealed that prescribers in the know ...

As the U.S. stock market navigates through a period of volatility driven by tariff news and economic data, major indexes like the Dow Jones, S&P 500, and Nasdaq Composite are showing resilience with ...

Learn about the significant threat of short squeezes and their effects on hedge funds as retail investors lead the charge.